A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects
A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects
To evaluate the effect of 6-month administration of CP-945,598 on:

 -  weight loss and waist circumference,

 -  blood pressure, cholesterol, glucose

 -  other biochemical variables like insulin, leptin, ghrelin, adiponectin, PAI 1, TNF-Î±
 and hsCRP

 -  the relationship between the concentration of the drug on the blood and the above
 parameters

 -  physical and psychosocial functioning, weight related symptoms, treatment satisfaction,
 appetite/hunger/satiety/craving and mood, anxiety, anhedonia and depression
Inclusion Criteria:

 -  Male and/or female subjects without clinically relevant abnormalities identified by a
 detailed medical history, full physical examination, including blood pressure and
 pulse rate measurements, 12 lead ECG and clinical laboratory tests

 -  Body Mass Index (BMI) Â³30 and <40 kg/m2, for subjects with no additional

 -  co morbidities; BMI Â³27 kg/m2 and <40 kg/m2, for subjects with co morbidities
 [history of essential hypertension and/or dyslipidemia defined as high LDL (Â³160
 mg/dL) or high total cholesterol (Â³240 mg/dL)];

 Exclusion Criteria:

 -  Subjects with resting sitting systolic blood pressure of 140 mmHg or greater or
 diastolic blood pressure of 90 mmHg or greater.

 -  Subjects with type 2 diabetes or fasting blood glucose concentration Â³126 mg/dL;

 -  Subjects with a history of eating disorders like anorexia nervosa or bulimia nervosa

 -  Subjects on prescription and non-prescription appetite or weight modifying drugs